FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Leukemia topics
Myelogenous
Myelogenous Leukemia
Proliferative
Autoimmune
Stem Cells
Breast Cancer
Rheumatoid Arthritis
Myeloid Leukemia
Acute Myelogenous Leukemia
Lymphocytic
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia
Epigenetic
Multiple Myeloma
Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukemia patents



      
           
This page is updated frequently with new Leukemia-related patent applications. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds. RSS updates for this page: Leukemia RSS RSS


Date/App# patent app List of recent Leukemia-related patents
01/22/15
20150025232
 Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells patent thumbnailnew patent Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells
There is provided a heptamer-type small guide nucleic acid that comprises any of the 7-base sequences of seq id nos: 1 to 15, and induces apoptosis of human leukemia cells. A leukemia therapeutic agent containing the heptamer-type small guide nucleic acid as an active ingredient is also provided.
01/22/15
20150025135
 Methods and compositions for treating leukemia patent thumbnailnew patent Methods and compositions for treating leukemia
The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds.. .
Golden Biotechnology Corporation
01/22/15
20150023964
 Fcgammariib-specific antibodies and methods of use thereof patent thumbnailnew patent Fcgammariib-specific antibodies and methods of use thereof
The present invention relates to antibodies or fragments thereof that specifically bind fcγriib, particularly human fcγriib, with greater affinity than the antibodies or fragments thereof bind fcγriia, particularly human fcγriia. The present invention also provides the use of an anti-fcγriib antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a b-cell malignancy, particularly, b-cell chronic lymphocytic leukemia or non-hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an ige-mediated allergic disorder, or one or more symptoms thereof.
Macrogenics, Inc.
01/22/15
20150023870
 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases patent thumbnailnew patent Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
Disclosed herein are compositions and methods of use comprising hexavalent dnl complexes. Preferably, the complexes comprise anti-cd20 and/or anti-cd22 antibodies or fragments thereof.
Ibc Pharmaceuticals, Inc.
01/15/15
20150018355
 Compounds and methods for treating leukemia patent thumbnailCompounds and methods for treating leukemia
Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (all) in its various forms..
Indiana University Research And Technology Corporation
01/08/15
20150011628
 Substitute diphenylamine compounds use thereof as antitumor agents patent thumbnailSubstitute diphenylamine compounds use thereof as antitumor agents
The compound represented by formula (i) showed potent antitumor activity, especially to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The preferred cancers are: colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer, osteosarcoma, nasopharynx cancer or stomach cancer..
01/08/15
20150011618
 Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects patent thumbnailSynthesis of polyhydroxy chromenone compounds and their anti-tumor effects
The present invention is directed to chromenone compounds of formula (i), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor er-α36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc..
Beijing Shenogen Pharma Group Ltd.
01/08/15
20150010475
 Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all) patent thumbnailCrlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)
The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by crlf-2 and cd 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing crlf-2 and cd 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (all), including (b-precursor acute lymphoblastic leukemia (b-all). Novel crlf-2 binding peptides and clrf-2 and cd19-binding viral-like particles (vlps) useful in the treatment of cancer, including all are also provided..
Sanda Corporation
01/01/15
20150005361
 Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells patent thumbnailInduced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells
Disclosed herein are compositions and methods to treat and reduce therapeutic resistance in chronic myelogenous leukemia. Also disclosed herein are methods to generate leukemia stem cell like cells (ilscs) generated from cml patient-derived ipscs, and methods for utilizing ilscs in screens to identify modulators of cml drug resistance and gene targets that underlie cml drug resistance..
Wisconsin Alumni Research Foundation
12/25/14
20140378457
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140377220

Gene expression signatures for staging and prognosis of prostate, breast and leukemia cancers


The present invention is drawn to methods of assessing and treating cancers such as erg-related, prostate, breast and leukemia, by examining the expression of combinations of particular genes disregulated in this disease state. The combinations of genes are selected from the following genes: inhibitor of growth family, member 3 (hstg3); lymphoid enhancer-binding protein factor 1 (lef1); frizzled-related protein (frzb); annexin a4 (anxa4); meis homeobox 2 (meis2); syndecan binding protein (syntenin) (sdcbp); ankyrin 3, node of ranvier (ankyrin g) (ank3); chromodomain helicase dna binding protein 5 (chd5); phospholipase a2, group vii (platelet-activating factor acetylhydrolase, plasma) (pla2g7); and wingless-type mmtv integration site family member 2 (wnt2)..
Uti Limited Partnership
12/18/14
20140371306

Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases


The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from leontopodium alpinum cass. (edelweiss).
UniversitÄt Innsbruck
12/18/14
20140371239

Menin-mll inhibitors and methods of use thereof


The present invention relates generally to compounds that inhibit the binding of menin and mll or mll fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with mll oncoproteins (e.g., mll1, mll2, mll-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of mll1, mll2, mll fusion proteins, mll-ptd and/or menin..
Vanderbilt University
12/18/14
20140370039

Il-12 immunotherapy for cancer


Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
University Health Network
12/18/14
20140370023

Erg monoclonal antibodies


Monoclonal antibodies, or antigen-binding fragments thereof, that bind to erg, and more specifically, to an epitope formed by amino acids 42-66 of erg3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the cdr regions derived from those non-human antibodies.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
12/18/14
20140370010

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3


The invention provides methods and compositions comprising anti-epha3 antibodies for the treatment of myeloproliferative disorders.. .
Kalobios Pharmaceuticals, Inc.
12/18/14
20140369927

Camptothecin conjugates of anti-cd22 antibodies for treatment of b cell diseases


Disclosed herein are compositions and methods of use comprising combinations of anti-cd22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-cd22 antibody or may be separately administered, either before, simultaneously with or after the anti-cd22 antibody.
Immunomedics, Inc.
12/18/14
20140369924

Synergistic anti-cd47 therapy for hematologic cancers


Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for cd47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden.
The Board Of Trustees Of The Leland Stanford Junior University
12/11/14
20140364481

Rna chimeras in human leukemia and lymphoma


Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent rna fusions as diagnostic markers and clinical targets for leukemia..
12/11/14
20140364439

Markers associated with chronic lymphocytic leukemia prognosis and progression


The present invention provides methods and devices related to markers (or biomarkers) associated with chronic lymphocytic leukemia (cll). Examples of these markers include drivers of cll progression.
12/11/14
20140363424

Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant


The use of anti-cd20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of b-cell-related diseases, e.g., b-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients..
12/04/14
20140357604

Therapeutic composition for treating cancers


Disclosed herein is a composition that includes a novel combination of triterpenoids for the treatment or prophylaxis of a cancer. The triterpenoids includes at least ganoderic acid s (gas), ganoderic acid t (gat), ganoderic acid me (game), ganoderic acid r (gar), and ganodermic acid s (gmas).
11/27/14
20140350070

Combination therapy for mds


Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (mds) and acute myeloid leukemia (aml). The disclosed methods include administering to an individual in need of such treatment a composition that may include an irak1/4 inhibitor.
11/27/14
20140349955

Use of fluorine-containing water soluble platinum complex in preparing drugs for prevention and treatment of cancers


Disclosed in the present invention is the use of a fluorine-containing in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (i). Experiments have demonstrated that the present fluorine-containing water soluble platinum complex is highly water soluble and exhibiting superior cytotoxicity and efficacy compare to the clinical platinum drugs.
11/27/14
20140348902

Tcl1 peptides for immunotherapy


Provided are tcl1 peptides that bind to mhc i (hla-a2) on tumor cells or other antigen-presenting cells and are recognized by t-cell receptors on t cells. The tcl1 peptides may be therapeutically used to treat a cancer, such as a b cell malignancy, leukemia, or lymphoma.
11/27/14
20140348840

Method of treating and reducing the risk of acute myelogenous leukemia


The present invention relates to methods and compositions for treating and reducing the risk of acute myelogenous leukemia (aml). In particular, the invention provides methods for identifying novel treatments for aml based on reproducible and detectable changes in aml1-eto acetylation.
11/27/14
20140348823

Histone deacetylase (hdac) inhibitors for the treatment of cancer


The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (hdac) inhibitor as described herein, for example, pxd-101.
11/20/14
20140343051

Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation


Screening assays to identify compounds that may be useful for inhibiting and/or eliminating aml initiating cells using ahr modulators and/or the compounds of formula i or ii are also disclosed. The use of pharmaceutically acceptable agonists of the ahr for preventing or inhibiting minimal residual disease (mrd) in an aml patient is also disclosed..
11/20/14
20140342374

Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof


The present invention relates to a cd43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a cd43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma..
11/20/14
20140341910

Anti-human cd52 immunoglobulins


The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
11/20/14
20140341806

Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma


The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-hodgkin's lymphomas (nhl) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers.
11/13/14
20140336360

Tyrosine, serine and threonine phosphorylation sites


The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including aqua peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.. .
11/13/14
20140335018

Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging


The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e.
11/06/14
20140329815

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
10/30/14
20140322810

Natural and synthetic compounds for treating cancer and other diseases


This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
10/30/14
20140322253

Cyclin a1-targeted t-cell immunotherapy for cancer


Compositions and methods are provided for eliciting antigen-specific t-cell responses against human cyclin a1 (ccna1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (aml) including leukemia stem cells (lsc) and in immunologically privileged testis cells, but not in other normal cell types. Ccna1-derived peptide epitopes that are immunogenic for t-cells including ctl are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells..
10/30/14
20140322212

Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells


The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (aml) and b-cell acute lymphoid leukemia (b-all). The invention also relates to at least one chimeric antigen receptor (car) specific to cd123, vectors comprising the same, and recombinant t cells comprising the cd123 car.
10/30/14
20140322208

Treatment of hematologic malignancies with an anti-cxcr4 antibody


The present disclosure provides human monoclonal antibodies that bind specifically to cxcr4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a cxcr4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-cxcr4 antibody of the disclosure.
10/30/14
20140322166

Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia


The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of b-precursor acute lymphoblastic leukemia (all) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy.. .


Popular terms: [SEARCH]

Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.5628

3582

1 - 1 - 72